Video
Dr. Klotz discusses accuracy of miR Sentinel PCC4 Test for prostate cancer
Author(s):
“We think given the accuracy that this is potentially a game changer,” says Laurence Klotz, MD, FRCSC.
Video Player is loading.
In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it is advantageous compared to other currently available prostate cancer tests. Klotz is a professor of surgery at the University of Toronto, and the chair of prostate cancer research at the Sunnybrook Health Sciences Centre, Ontario, Canada.
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
